[1] AGYEMAN AA, BERGEN PJ, RAO GG, et al.A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections[J].Int J Antimicrob Agents, 2020, 55(1):105833. doi: 10.1016/j.ijantimicag.2019.10.014
[2] RODRÍGUEZ CH, NASTRO M, FAMIGLIETTI A.Carbapenemases in Acinetobacter baumannii.Review of their dissemination in Latin America[J].Rev Argent Microbiol, 2018, 50(3):327.
[3] TÄNGDÉN T, GISKE CG.Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection, treatment and infection control[J].Intern Med, 2015, 277(5):501. doi: 10.1111/joim.12342
[4] 唐翔, 卓超, 徐英春, 等.全国多中心呼吸科住院患者下呼吸道和血液分离菌的构成及耐药性分析[J].中华结核和呼吸杂志, 2018, 41(4):281.
[5] 张弨, 翟所迪, 单爱莲.替加环素的药代动力学/药效学评价和剂量选择研究现状[J].中国临床药理学杂志, 2016, 32(20):1914.
[6] ZHANEL GG, KARLOWSKY JA, RUBINSTEIN E, et al.Tigecycline:a novel glycylcycline antibiotic[J].Expert Rev Anti Infect Ther, 2006, 4(1):9. doi: 10.1586/14787210.4.1.9
[7] NI W, HAN Y, ZHAO J, et al.Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections:a systematic review and meta-analysis[J].Int J Antimicrob Agents, 2016, 47(2):107. doi: 10.1016/j.ijantimicag.2015.11.011
[8] 抗菌药物临床试验技术指导原则写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志, 2014, 30(9):844.
[9] 中国医药教育协会感染疾病专业委员会, 中华结核和呼吸杂志编辑委员会, 中国药学会药物临床评价研究专业委员会.抗菌药物超说明书用法专家共识[J].中华结核和呼吸杂志, 2015(6):410.
[10] 中国卫生健康委员会医政医管局.替加环素临床应用评价细则[S].2018-9-21.
[11] DE PASCALE G, MONTINI L, PENNISI M, et al.High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J].Crit Care, 2014, 18(3):R90. doi: 10.1186/cc13858
[12] WU XM, ZHU YF, CHEN QY, et al.Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment:a retrospective case study[J].Biomed Res Int, 2016, 2016:8395268.
[13] 王远芳, 康梅.急诊科感染患者微生物标本送检及临床分离菌分布和耐药分析[J].中华急诊医学杂志, 2016, 25(4):429.
[14] RAMIREZ J, DARTOIS N, GANDJINI H, et al.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J].Antimicrob Agents Chemother, 2013, 57(4):1756. doi: 10.1128/AAC.01232-12
[15] 刘培培, 赵江.替加环素和头孢哌酮钠舒巴坦钠治疗多重耐药鲍曼不动杆菌肺炎的对比研究[J].药物与临床, 2019, 16(1):24.
[16] 李佳慧, 陈华乐, 张能华, 等.替加环素单药及与5种抗菌药物联用对耐碳青霉烯类鲍曼不动杆菌的体外抑菌及生物膜清除作用研究[J].中国抗生素杂志, 2018, 43(2:)121.
[17] 陈爱凤, 沈晓强, 丁士标, 等.替加环素治疗碳青霉烯类耐药肺炎克雷伯菌肺炎的临床疗效及预后分析[J].浙江医学, 2018, 40(3):258.
[18] 王佳, 骆霞, 王林海, 等.替加环素联合头孢哌酮舒巴坦钠治疗多重/泛耐药鲍曼不动杆菌致肺炎的Meta分析[J].临床药物治疗杂志, 2017, 15(1):38.